Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016

  • ID: 3802758
  • Drug Pipelines
  • 62 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • Kamada Ltd.
  • Polyphor Ltd.
  • MORE
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016

Summary

‘Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016’, provides in depth analysis on Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted pipeline therapeutics.

The report provides comprehensive information on the Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37)
- The report reviews Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • Kamada Ltd.
  • Polyphor Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Overview

Therapeutics Development

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Stage of Development

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Therapy Area

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Indication

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Companies

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Universities/Institutes

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Companies Involved in Therapeutics Development

Cantex Pharmaceuticals, Inc.

Chiesi Farmaceutici SpA

Kamada Ltd.

Polyphor Ltd.

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANV-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Brevenal - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-6014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Dormant Projects

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Discontinued Products

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Featured News & Press Releases

Jun 15, 2016: Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due to severe AAT deficiency

May 25, 2016: Kamadas Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform

Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Mar 28, 2016: Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency

Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia

Jan 06, 2016: Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease

Dec 02, 2015: Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes

Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I

Jul 06, 2015: Kamada Announces Publication in Pediatric Diabetes

Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01

May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting

May 06, 2015: Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin During the American Thoracic Society 2015 International Conference

Apr 01, 2015: Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary Alpha-1 Proteinase Inhibitor

Mar 23, 2015: Kamada Awarded European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 62List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Cantex Pharmaceuticals, Inc., H1 2016

Pipeline by Chiesi Farmaceutici SpA, H1 2016

Pipeline by Kamada Ltd., H1 2016

Pipeline by Polyphor Ltd., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Discontinued Products, H1 2016 45List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • Kamada Ltd.
  • Polyphor Ltd.
  • MORE
According to the author's, recently published report 'Neutrophil Elastase - Pipeline Review, H1 2016'; Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the author says; Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Neutrophil elastase is a serine proteinase. It is secreted from neutrophils. It is involved in inflammatory diseases, including idiopathic pulmonary fibrosis, rheumatoid arthritis, adult respiratory distress syndrome, and cystic fibrosis. It modifies the functions of natural killer cells, monocytes and granulocytes. It inhibits C5a-dependent neutrophil enzyme release and chemotaxis.

The report 'Neutrophil Elastase - Pipeline Review, H1 2016' outlays comprehensive information on the Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 5
Cantex Pharmaceuticals, Inc.
Chiesi Farmaceutici SpA
Kamada Ltd.
Polyphor Ltd.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll